



TALTZ (ixekizumab)

Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

<u>Part A – Patient</u> Patient Information

Fatient information						
First Name:			Last Name:			
Insurance Carrier Name/Number:						
Group Number:			Client ID:			
Date of Birth (YYYY/MM/DD):			Relationship: Employee Spouse Dependent			
Language: English French			Gender: Male Female			
Address:						
City:		Province:		Postal Code:		
Email address:						
Telephone (home):		Telephone (cell):		Telephone (work):		
Please check any box that applies to the patient: The patient is an over-age student dependent (i.e. attending University or College full-time). A copy of the enrolment document from the educational institution confirming full-time status is enclosed. The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.						
Coordination of benefits						
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.					
Primary Coverage	Has the patient applied for reimbursement under a primary plan? Yes No N/A What is the coverage decision of the drug? Approved Denied *Attach decision letter*					





TALTZ (ixekizumab)

Authorization

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Debiant Cignature (if aver 40 years of age)	Data
Patient Signature (if over 18 years of age)	Date





TALTZ (ixekizumab)

Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

ALT7 (ivalsiaumah)		□ Na		
ALTZ (ixekizumab)		New r	equest R	enewal request*
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
te of drug administrat	l ion:			
Home Phys	ician's office/Private Clin	ic Private Clinic (within Ho	spital - no public or	government funding)
] Hospital (inpatient)	Hospital (outpati	ient)		
ame of the hospital or	private clinic:			
ddress:				
City: Pro		vince:	Postal code:	
ity.	1100	Allice.	i ostai code.	
* Please submit proof	of prior coverage if avail	ahle		
* Please submit proof	of prior coverage if avail	able		
·		able		
ECTION 2 – ELIGIB	ILITY CRITERIA			
ECTION 2 – ELIGIB				
ECTION 2 - ELIGIB	ILITY CRITERIA			
ECTION 2 - ELIGIB Please indicate if the Plaque Psoriasis	ILITY CRITERIA he patient satisfies the b			
ECTION 2 - ELIGIBLE Please indicate if the laque Psoriasis For the treatment of the patient harmonic in the patient harmonic	ILITY CRITERIA he patient satisfies the b ent of moderate to sever	elow criteria:		t of the patient's face
L. Please indicate if the Plaque Psoriasis For the treatment has been proceed by the patient	ILITY CRITERIA he patient satisfies the b ent of moderate to seven s an affected body surface genital region, AND	elow criteria: e plaque psoriasis in an adult, AND	there is involvemen	t of the patient's face
Please indicate if the Plaque Psoriasis For the treatment of the patient hands, feet or The patient hands, feet or	the patient satisfies the beent of moderate to sever an affected body surface genital region, AND as a Psoriasis Area and Sees had an inadequate resi	elow criteria: e plaque psoriasis in an adult, AND ce area (BSA) of 10% or greater, or	there is involvemen reater, AND	
Please indicate if the Plaque Psoriasis For the treatment of the patient hands, feet or The patient hands inaccessible, A. The patient hands inaccessible of the patient hands in the patient hand	ent of moderate to sever s an affected body surface genital region, AND s a Psoriasis Area and Se s had an inadequate resi	elow criteria: e plaque psoriasis in an adult, AND ce area (BSA) of 10% or greater, or a	there is involvemen reater, AND ance to phototherap	by, unless it is
ECTION 2 - ELIGIBI L. Please indicate if the Plaque Psoriasis For the treatment has hands, feet or The patient has inaccessible, A The patient has to another biol	ent of moderate to sever s an affected body surface genital region, AND s a Psoriasis Area and Se s had an inadequate resi	elow criteria: e plaque psoriasis in an adult, AND ce area (BSA) of 10% or greater, or everity Index (PASI) score of 10 or g ponse or has a documented intolera	there is involvemen reater, AND ance to phototherap	by, unless it is
Please indicate if the Plaque Psoriasis For the treatment has a hands, feet or hands, feet or hands hands. The patient has inaccessible, A hands hand	ent of moderate to sever s an affected body surface genital region, AND s a Psoriasis Area and Se s had an inadequate resi	elow criteria: e plaque psoriasis in an adult, AND ce area (BSA) of 10% or greater, or everity Index (PASI) score of 10 or g ponse or has a documented intolera ponse or has a documented intolera	there is involvemen reater, AND ance to phototherap	by, unless it is





TALTZ (ixekizumab)

Ankylosing Spondylitis						
For the treatment of ankylosing spondylitis in an adult, AND						
The patient has a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of 4 or greater on a 10-point scale, AND						
The patient has had an inadequate response or has a documented intolerance to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) for a minimum of 2 weeks each, or to at least 2 disease modifying anti-rheumatic drugs (DMARDs) for a minimum of 3 months, or to another biologic response modifier						
Non-Radiographic Axial Spondyloarthritis						
For the treatment of non-radiographic axial spondyloarthritis in an adult, AND						
The patient has objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), AND						
The patient has had an inadequate response or has a documented intolerance to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) for a minimum of 2 weeks each, or to another biologic response modifier						
OR None of the above criteria applies. Relevant additional information:						
SECTION 3 - PRESCRIBER INFORMATION						
Physician's Name:						
Address:						
Tel:	Fax:					
License No.:	Specialty:					
Physician Signature:	Date:					





TALTZ (ixekizumab)

SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at www.sunlife.ca/privacy or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET

SECTION 5 - CONTACT US

You can submit **all** pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the reference number.

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, OC H3C 6C1 Sun Life Assurance Company of Canada Attention: Claims Dept. PO Box 2010 STN Waterloo

Waterloo, ON N2J 0A6